CPRX.NASDAQCatalyst Pharmaceuticals, INC

Form 4: Catalyst Pharmaceuticals Executive Reports Stock Transaction

Sentiment:

Insider Transaction (Form 4)

📋All filings for Catalyst Pharmaceuticals, INC
🔒Login to Follow

Brian Elsbernd, Chief Legal Officer of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.

Summary

  • Disposition to the issuer: disposed of 242,501 Common Stock, par value $0.001 per share at $31.50 ($7,638,782) on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 132,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 200,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 135,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 69,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 147,621 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 126,704 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 98,652 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 7,067 Restricted Stock Units on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 10,322 Restricted Stock Units on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 29,776 Restricted Stock Units on July 15, 2026 (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Brian Elsbernd — Officer (Chief Legal Officer)

DateTransactionSecuritySharesPriceValueHeld After
2026-07-15Disposition to the issuerCommon Stock, par value $0.001 per share242,501$32$7.6M0
2026-07-15Disposition to the issuerOptions to purchase common stock132,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock200,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock135,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock69,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock147,621——0
2026-07-15Disposition to the issuerOptions to purchase common stock126,704——0
2026-07-15Disposition to the issuerOptions to purchase common stock98,652——0
2026-07-15Disposition to the issuerRestricted Stock Units7,067——0
2026-07-15Disposition to the issuerRestricted Stock Units10,322——0
2026-07-15Disposition to the issuerRestricted Stock Units29,776——0

Key Dates

DateDescription
2026-07-15Disposition to the issuer (242,501 shares)
2026-07-15Disposition to the issuer (132,000 shares)
2026-07-15Disposition to the issuer (200,000 shares)
2026-07-15Disposition to the issuer (135,000 shares)
2026-07-15Disposition to the issuer (69,000 shares)
2026-07-15Disposition to the issuer (147,621 shares)
2026-07-15Disposition to the issuer (126,704 shares)
2026-07-15Disposition to the issuer (98,652 shares)
2026-07-15Disposition to the issuer (7,067 shares)
2026-07-15Disposition to the issuer (10,322 shares)
2026-07-15Disposition to the issuer (29,776 shares)

Keywords

insider transaction, Form 4, CPRX, CATALYST PHARMACEUTICALS, INC., neutral, Brian Elsbernd

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.